ArticleBMC biology2025
BertADP: a fine-tuned protein language model for anti-diabetic peptide prediction.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- iBitter-HF: A Method for Bitter Peptide Sequence Identification Based on Hybrid Feature Embedding.Foods (Basel, Switzerland) · 2026Article
- Food-Derived Antidiabetic Peptides as Multi-Target Systemic Regulators: A Comprehensive Review of Sources, Preparation, Mechanisms and Future Perspectives.Foods (Basel, Switzerland) · 2026Review
- NeuroPred-GMC: a dual-branch deep learning architecture for neuropeptide prediction based on gated dilated convolutional network and multi-scale convolutional network.Journal of computer-aided molecular design · 2026Article
- De novo generation and in silico screening of anti-diabetic peptide candidates via a deep learning-attention framework with physicochemical feature fusion.Scientific reports · 2026Article
- A Multi-Omics Integration Framework with Automated Machine Learning Identifies Peripheral Immune-Coagulation Biomarkers for Schizophrenia Risk Stratification.International journal of molecular sciences · 2025Article
- BertADP: a fine-tuned protein language model for anti-diabetic peptide prediction.BMC biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetes is a global metabolic disease that urgently calls for the development of new and effective therapeutic agents. Anti-diabetic peptides (ADPs) have emerged as a research hotspot due to their therapeutic potential and natural safety, representing a promising class of functional peptides for diabetic management. However, conventional computational approaches for ADPs prediction mainly rely on manually extracted sequence features. These methods often lack generalizability and perform poorly on short peptides, thereby hindering effective ADPs discovery.
resultsIn this study, we introduce a fine-tuning strategy of large-scale pre-trained protein language models (PLMs) for ADPs prediction, enabling automated extraction of discriminative semantic representations. We established the most comprehensive ADPs dataset to date, comprising 899 rigorously curated non-redundant ADPs and 67 newly collected potential candidates. Based on three model construction strategies, we developed 11 candidate models. Among them, BertADP (a fine-tuned ProtBert model) demonstrated superior performance in the independent test set, outperforming existing ADPs prediction tools with an overall accuracy of 0.955, sensitivity of 1.000, and specificity of 0.910. Notably, BertADP exhibited remarkable sequence length adaptability, maintaining stable performance across both standard and short peptide sequences.
conclusionsBertADP represents the first PLMs-based intelligent prediction tool for ADPs, whose exceptional identification capability will significantly accelerate anti-diabetic drug development and facilitate personalized therapeutic strategies, thereby enhancing precision diabetes management. Furthermore, the proposed approach provides a generalizable framework that can be extended to other bioactive peptide discovery studies, offering an innovative solution for bioactive peptide mining.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.